Risk Factors for Cisplatin-Induced Nephrotoxicity and Potential of Magnesium Supplementation for Renal Protection

Yasuhiro Kidera1,2*, Hisato Kawakami3**, Tsutomu Sakiyama3, Kunio Okamoto3, Kaoru Tanaka3, Masayuki Takeda3, Hiroyasu Kaneda3, Shin-ichi Nishina3, Junji Tsurutani3, Kimiko Fujiwara2, Morihiro Nomura2, Yuzuru Yamazoe2, Yasutaka Chiba4, Shozo Nishida1, Takao Tamura3, Kazuhiko Nakagawa3

1 Division of Pharmacotherapy, Kinki University Faculty of Pharmacy, Higashi-Osaka, Osaka, Japan, 2 Department of Pharmacy, Kinki University Faculty of Medicine, Osaka-Sayama, Osaka, Japan, 3 Department of Medical Oncology, Kinki University Faculty of Medicine, Osaka-Sayama, Osaka, Japan, 4 Division of Biostatistics, Clinical Research Center, Kinki University Faculty of Medicine, Osaka-Sayama, Osaka, Japan

Abstract

Background: Nephrotoxicity remains a problem for patients who receive cisplatin chemotherapy. We retrospectively evaluated potential risk factors for cisplatin-induced nephrotoxicity as well as the potential impact of intravenous magnesium supplementation on such toxicity.

Patients and Methods: We reviewed clinical data for 401 patients who underwent chemotherapy including a high dose ($\geq 60 \text{ mg/m}^2$) of cisplatin in the first-line setting. Nephrotoxicity was defined as an increase in the serum creatinine concentration of at least grade 2 during the first course of cisplatin chemotherapy, as assessed on the basis of National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. The severity of nephrotoxicity was evaluated on the basis of the mean change in the serum creatinine level. Magnesium was administered intravenously to 67 patients (17%).

Results: Cisplatin-induced nephrotoxicity was observed in 127 patients (32%). Multivariable analysis revealed that an Eastern Cooperative Oncology Group performance status of 2 (risk ratio, 1.876; $P = 0.004$) and the regular use of nonsteroidal anti-inflammatory drugs (NSAIDs) (risk ratio, 1.357; $P = 0.047$) were significantly associated with an increased risk for cisplatin nephrotoxicity, whereas intravenous magnesium supplementation was associated with a significantly reduced risk for such toxicity (risk ratio, 0.175; $P = 0.0004$). The development of hypomagnesemia during cisplatin treatment was significantly associated with a greater increase in serum creatinine level ($P = 0.0025$). Magnesium supplementation therapy was also associated with a significantly reduced severity of renal toxicity ($P = 0.012$).

Conclusions: A relatively poor performance status and the regular use of NSAIDs were significantly associated with cisplatin-induced nephrotoxicity, although the latter association was marginal. Our findings also suggest that the ability of magnesium supplementation to protect against the renal toxicity of cisplatin warrants further investigation in a prospective trial.

Introduction

Cisplatin (cis-diammine-dichloroplatinum), an inorganic platinum chemotherapeutic drug, has been widely administered either alone or in combination with other agents for the clinical treatment of various solid tumors [1]. The efficacy of cisplatin is limited, however, by severe side effects such as nephrotoxicity, neurotoxicity, ototoxicity, and emetogenicity [2,3]. In particular, the nephrotoxicity of cisplatin is dose dependent and therefore limits the amount of drug that can be administered [4]. Procedures to reduce such toxicity include aggressive hydration with saline and simultaneous administration of mannitol, which is now accepted as the standard of care for individuals treated with regimens containing a high dose ($\geq 60 \text{ mg/m}^2$) of cisplatin [5]. Unfortunately, renal toxicity still occurs even with such hydration, highlighting the need for more effective preventive strategies. Another approach to limiting the nephrotoxicity of cisplatin is intravenous magnesium supplementation. Cisplatin-induced nephrotoxicity is accompanied by disturbance of the renal handling of...
electrolytes. In particular, depletion of magnesium has emerged as a common event associated with the acute renal toxicity induced by the drug [6]. Whereas several studies have demonstrated the efficacy of magnesium supplementation for prevention of hypomagnesemia during cisplatin treatment [7–10], only two prospective studies, each featuring a relatively small number of patients, have evaluated its efficacy in terms of protection against cisplatin-induced nephrotoxicity [11,12]. Despite the dearth of evidence in support of a beneficial effect of magnesium supplementation therapy on the renal toxicity of cisplatin, intravenous administration of magnesium is currently recommended for outpatients receiving high-dose cisplatin with a short hydration regimen [13]. We have therefore recently applied this procedure to all patients who receive such chemotherapy. However, given that magnesium supplementation has not been accepted as the standard of care, at least in Japan, most patients who receive high-dose cisplatin are treated with aggressive hydration in the inpatient setting.

We have now assessed a large group of unselected consecutive patients in an attempt to identify potential biological or pharmacological parameters that might predispose individuals to cisplatin-induced nephrotoxicity. We also retrospectively evaluated the potential impact of intravenous magnesium supplementation on this side effect of cisplatin treatment.

Patients and Methods

Eligibility criteria

We reviewed the cases in our database and retrospectively examined the clinical data of patients who received therapy including a high dose (≥60 mg/m²) of cisplatin in the first-line setting at the Department of Medical Oncology, Kinki University Hospital, between January 2008 and August 2012. Patients were eligible if they had pathologically confirmed malignancies and an Eastern Cooperative Oncology Group performance status (PS) of 0 to 2. Patients were excluded from the study if they had a history of cisplatin treatment or had more than one cancer. The study protocol was approved by the ethics committee of Kinki University Hospital with the condition that all data be processed and analyzed anonymously, and written informed consent was provided by all patients. The study also conforms with the provisions of the Declaration of Helsinki.

Cisplatin administration

All regimens containing high-dose cisplatin were administered in the inpatient setting. Cisplatin was administered in 500 mL of 0.9% normal saline over 1 h. Most patients were prehydrated with 500 mL of one-quarter isotonic saline containing 5% glucose and 20 mEq of KCl, and they were posthydrated with 500 mL of 0.9% normal saline mixed with 500 mL of one-quarter isotonic saline containing 5% glucose, 20 mEq of KCl, and 10 mEq of sodium L-lactate, which was administered over 1 to 2 h and followed by 60 g of mannitol over 1 h and 20 mg of furosemide in 50 mL of 0.9% normal saline over 15 min. Antiemetic prophylaxis with 5-HT3 antagonist, and regular use of nonsteroidal anti-inflammatory drugs (NSAIDs). The risk factors were also evaluated in multivariable analysis with the Poisson regression model. The risk ratio with 95% confidence interval (CI) was calculated for the independent prognostic factors. The mean change in serum creatinine concentration was compared between groups with the use of box-and-whisker plots showing the range (maximum and minimum), median, and quartile range (75 and 25 percentiles) and was evaluated with the unpaired Student’s t test. Statistical analysis was performed with the use of SAS software version 9.4 (SAS Institute, Cary, NC). A P value of <0.05 was considered statistically significant.

Results

Patient characteristics

A total of 401 patients who received chemotherapy including high-dose cisplatin were eligible for the analysis. Baseline characteristics of the eligible patients are summarized in Table 1. The median age was 65 years (range, 28–80), and most patients were male (77%) and had a good PS of 0 or 1 (94%). The most common malignancies were lung cancer (36%), head and neck cancer (23%), gastric cancer (19%), and esophageal cancer (16%). Median age, sex, PS, median serum creatinine concentration at baseline, median body surface area, median body mass index, and the median dose of cisplatin in the first course of chemotherapy did not differ significantly among the types of malignancy. The various chemotherapy regimens administered to the patients are shown in Table S1.
Table 1. Baseline characteristics of the 401 study patients.

| Characteristic                        | All patients (n = 401) | Lung cancer (n = 144) | Head and neck cancer (n = 92) | Gastric cancer (n = 78) | Esophageal cancer (n = 65) | Other malignancies (n = 22) |
|---------------------------------------|------------------------|-----------------------|-------------------------------|------------------------|---------------------------|-----------------------------|
| Sex                                   |                        |                       |                               |                        |                           |                             |
| Male                                  | 308 (77)               | 107                   | 74                            | 57                     | 54                        | 16                          |
| Female                                | 93 (23)                | 37                    | 18                            | 21                     | 11                        | 6                           |
| PS                                    |                        |                       |                               |                        |                           |                             |
| 0–1                                   | 375 (94)               | 139                   | 89                            | 67                     | 61                        | 19                          |
| 2                                     | 26 (6)                 | 5                     | 3                             | 11                     | 4                         | 3                           |
| Baseline Cr (mg/dL)                   |                        |                       |                               |                        |                           |                             |
| Median                                | 0.69                   | 0.67                  | 0.68                          | 0.73                   | 0.72                      | 0.71                        |
| (range)                               | (0.23–1.31)            | (0.39–1.11)           | (0.24–1.15)                   | (0.23–1.31)            | (0.40–1.10)               | (0.49–1.08)                 |
| BSA (m²)                              |                        |                       |                               |                        |                           |                             |
| Median                                | 1.61                   | 1.62                  | 1.56                          | 1.60                   | 1.60                      | 1.60                        |
| (range)                               | (1.15–2.21)            | (1.29–2.21)           | (1.29–1.96)                   | (1.22–1.90)            | (1.15–1.87)               | (1.28–1.92)                 |
| BMI (kg/m²)                           |                        |                       |                               |                        |                           |                             |
| Median                                | 21.1 (11.6–35.3)       | 22.2 (14.9–35.3)      | 20.9 (11.6–34.0)              | 20.9 (15.2–33.5)       | 20.5 (13.4–28.1)          | 20.6 (16.4–28.8)            |
| (range)                               |                        |                       |                               |                        |                           |                             |
| Cisplatin dose (mg/m²)                |                        |                       |                               |                        |                           |                             |
| Median                                | 78.0                   | 78.7                  | 80.0                          | 60.0                   | 70.0                      | 79.8                        |
| (range)                               | (60.0–105)             | (60.0–80.3)           | (60.0–105)                    | (60.0–84.0)            | (60.0–80.0)               | (60.0–100)                 |
| Age (years)                           |                        |                       |                               |                        |                           |                             |
| Median                                | 65                     | 64                    | 62                            | 67                     | 67                        | 64                          |
| (range)                               | (28–80)                | (33–80)               | (30–79)                       | (28–80)                | (51–78)                   | (37–75)                     |
| Concurrent radiation                  |                        |                       |                               |                        |                           |                             |
| Yes                                   | 167 (42)               | 45                    | 60                            | 1                      | 50                        | 11                          |
| No                                    | 234 (58)               | 99                    | 32                            | 77                     | 15                        | 11                          |
| Hypoalbuminemia (serum albumin, <3.0 g/dL) |                        |                       |                               |                        |                           |                             |
| Yes                                   | 43 (11)                | 14                    | 3                             | 18                     | 8                         | 0                           |
| No                                    | 358 (89)               | 130                   | 89                            | 60                     | 57                        | 22                          |
| Enteral nutrition or TPN              |                        |                       |                               |                        |                           |                             |
| Yes                                   | 42 (10)                | 2                     | 20                            | 2                      | 16                        | 2                           |
| No                                    | 359 (90)               | 142                   | 72                            | 76                     | 49                        | 20                          |
| Type 2 diabetes                       |                        |                       |                               |                        |                           |                             |
| Yes                                   | 99 (25)                | 39                    | 30                            | 15                     | 11                        | 4                           |
| No                                    |                        |                       |                               |                        |                           |                             |
Table 1. Cont.

| Characteristic                              | All patients (n = 401) | Lung cancer (n = 144) | Head and neck cancer (n = 92) | Gastric cancer (n = 78) | Esophageal cancer (n = 65) | Other malignancies (n = 22) |
|---------------------------------------------|------------------------|-----------------------|-------------------------------|------------------------|---------------------------|-----------------------------|
| Hydration of ≤2000 mL                       |                        |                       |                               |                        |                           |                             |
| Yes                                         | 230 (57)               | 66                    | 68                            | 46                     | 38                        | 12                          |
| No                                          | 171 (43)               | 78                    | 24                            | 32                     | 27                        | 10                          |
| Use of NK1 receptor antagonist              |                        |                       |                               |                        |                           |                             |
| Yes                                         | 164 (41)               | 56                    | 39                            | 33                     | 28                        | 8                           |
| No                                          | 237 (59)               | 88                    | 53                            | 45                     | 37                        | 14                          |
| Intravenous magnesium supplementation       |                        |                       |                               |                        |                           |                             |
| Yes                                         | 157 (39)               | 55                    | 44                            | 24                     | 28                        | 6                           |
| No                                          | 244 (61)               | 89                    | 48                            | 54                     | 37                        | 16                          |
| Oral intake of magnesium oxide as a laxative agent |                    |                       |                               |                        |                           |                             |
| Yes                                         | 117 (29)               | 51                    | 30                            | 18                     | 11                        | 7                           |
| No                                          | 284 (71)               | 93                    | 62                            | 60                     | 54                        | 15                          |

Drug administration variables refer to the first course of cisplatin chemotherapy. Abbreviations: PS, performance status; Cr, serum creatinine concentration; BSA, body surface area; BMI, body mass index; TPN, total parenteral nutrition; NK1, neurokinin 1; NSAIDs, nonselective nonsteroidal anti-inflammatory drugs.
| Characteristic                          | Cisplatin nephrotoxicity | P value |
|----------------------------------------|--------------------------|---------|
|                                        | Yes (n=127) | No (n=274) |
|                                        | n (%)     | n (%)     |
| **Age (years)**                        |            |           |
| Median                                 | 65         | 65        |
| (range)                                | (37–80)    | (28–80)   |
| ≥70                                    | 31 (32)    | 66 (68)   |
| <70                                    | 96 (32)    | 208 (68)  |
| **Sex**                                |            |           |
| Male                                   | 97 (31)    | 211 (69)  |
| Female                                 | 30 (32)    | 63 (68)   |
| **PS**                                 |            |           |
| 0 or 1                                 | 111 (30)   | 264 (70)  |
| 2                                      | 16 (62)    | 10 (38)   |
| **Tumor type**                         |            |           |
| Lung                                   | 40 (28)    | 104 (72)  |
| Head and neck                          | 28 (30)    | 64 (70)   |
| Gastric                                | 23 (29)    | 55 (71)   |
| Esophageal                             | 31 (48)    | 34 (52)   |
| Other                                  | 5 (23)     | 17 (77)   |
| **Concurrent radiation**               |            |           |
| Yes                                    | 56 (34)    | 111 (66)  |
| No                                     | 71 (30)    | 163 (70)  |
| **Hypoalbuminemia (serum albumin, <3.0 g/dL)** |            |           |
| Yes                                    | 15 (35)    | 28 (65)   |
| No                                     | 112 (31)   | 246 (69)  |
| **Enteral nutrition or TPN**           |            |           |
| Yes                                    | 17 (40)    | 25 (60)   |
| No                                     | 110 (31)   | 249 (69)  |
| **Type 2 diabetes**                    |            |           |
| Yes                                    | 26 (26)    | 73 (74)   |
| No                                     | 101 (33)   | 201 (67)  |
| **Hydration of ≤2000 mL**              |            |           |
| Yes                                    | 13 (38)    | 21 (62)   |
| No                                     | 114 (31)   | 253 (69)  |
| **Use of NK1 receptor antagonist**     |            |           |
| Yes                                    | 61 (27)    | 169 (73)  |
| No                                     | 66 (39)    | 105 (61)  |
| **Intravenous magnesium supplementation** |          |           |
| Yes                                    | 4 (6)      | 63 (94)   |
| No                                     | 123 (37)   | 211 (63)  |
| **Oral intake of magnesium oxide as a laxative agent** |          |           |
| Yes                                    | 48 (29)    | 116 (71)  |
| No                                     | 79 (33)    | 158 (67)  |
| **Regular use of antihypertensive**    |            |           |
| Yes                                    | 51 (32)    | 106 (68)  |
| No                                     | 76 (31)    | 168 (69)  |
Clinicopathologic analysis of risk factors for cisplatin nephrotoxicity

Cisplatin-induced nephrotoxicity was observed in 127 (32%) of the 401 enrolled patients, including 108, 16, and 3 patients with nephrotoxicity of grade 2, 3, and 4, respectively. Among these patients, 55 individuals developed irreversible renal failure. Fisher’s exact test revealed that a PS of 2 (P = 0.002), the absence of intravenous magnesium supplementation (P = 0.0001), and the lack of treatment with an NK1 receptor antagonist (P = 0.013) were significantly associated with cisplatin nephrotoxicity (Table 2). We also detected significant heterogeneity in the occurrence of nephrotoxicity among tumor types (P = 0.045). Examination of the possible impact of concurrent chemotherapy agents on the prevalence of nephrotoxicity (Table S2) revealed no significant association between the use of these agents and such toxicity (P = 0.373).

Multivariable analysis of risk factors for cisplatin nephrotoxicity

To assess the contribution of each individual risk factor to cisplatin-induced nephrotoxicity, we performed multivariable analysis (Table 3). A PS of 2 (risk ratio, 1.876; 95% CI, 1.229–2.864; P = 0.004) and regular use of NSAIDs (risk ratio, 1.357; 95% CI, 1.004–1.835; P = 0.047) were significantly associated with an increased risk for cisplatin nephrotoxicity, whereas intravenous magnesium supplementation (risk ratio, 0.175; 95% CI, 0.066–0.462; P = 0.0004) was associated with a significantly reduced risk. We also found that esophageal cancer was an independent risk factor for nephrotoxicity compared with lung cancer (risk ratio,

Table 2. Cont.

| Characteristic                | Cisplatin nephrotoxicity | P value |
|------------------------------|--------------------------|---------|
|                              | Yes (n=127) | No (n=274) |         |
|                              | n (%)       | n (%)     |         |
| Regular use of NSAIDs        |             |           |         |
| Yes                          | 44 (38)     | 73 (62)   | 0.125   |
| No                           | 83 (29)     | 201 (71)  |         |

Drug administration variables refer to the first course of cisplatin chemotherapy. Abbreviations: PS, performance status; TPN, total parenteral nutrition; NK1, neurokinin 1; NSAIDs, nonselective nonsteroidal anti-inflammatory drugs.

*P value for heterogeneity for the occurrence of nephrotoxicity among tumor types. P values of <0.05 are shown in bold.

doi:10.1371/journal.pone.0101902.t002

Table 3. Risk ratio in multivariable analysis of potential predisposing factors for cisplatin-induced nephrotoxicity (n=401).

| Factor                                      | Risk ratio | 95% CI    | P value |
|---------------------------------------------|------------|-----------|---------|
| Age (≥70 vs. <70 years)                     | 1.006      | 0.990–1.023 | 0.475   |
| Sex (male vs. female)                       | 0.947      | 0.683–1.314 | 0.745   |
| PS (2 vs. 0 or 1)                           | 1.876      | 1.229–2.864 | 0.004   |
| Concurrent radiation                        | 1.071      | 0.769–1.491 | 0.684   |
| Serum albumin (≥3.0 vs. <3.0 g/dL)          | 0.897      | 0.693–1.165 | 0.419   |
| Enteral nutrition or TPN                    | 0.989      | 0.643–1.520 | 0.959   |
| Type 2 diabetes                             | 0.872      | 0.599–1.270 | 0.476   |
| Hydration (≥2000 or >2000 mL)               | 0.801      | 0.536–1.200 | 0.283   |
| Use of NK1 receptor antagonist              | 0.878      | 0.663–1.163 | 0.363   |
| Intravenous magnesium supplementation        | 0.175      | 0.066–0.462 | 0.0004  |
| Oral intake of magnesium oxide as a laxative agent | 0.933 | 0.703–1.240 | 0.634   |
| Regular use of antihypertensive             | 1.010      | 0.810–1.485 | 0.553   |
| Regular use of NSAIDs                       | 1.357      | 1.004–1.835 | 0.047   |
| Tumor type                                  |            |           |         |
| Lung                                        | 1.000      |           |         |
| Head and necka                              | 1.301      | 0.845–2.010 | 0.232   |
| Gastricaa                                   | 1.071      | 0.678–1.692 | 0.770   |
| Esophagealaa                                | 1.937      | 1.277–2.940 | 0.002   |
| Otheraa                                     | 0.810      | 0.360–1.823 | 0.610   |

Drug administration variables refer to the first course of cisplatin chemotherapy. Abbreviations: CI, confidence interval; PS, performance status; TPN, total parenteral nutrition; NK1, neurokinin 1; NSAIDs, nonselective nonsteroidal anti-inflammatory drugs.

*These risk factors were compared with lung cancer.

doi:10.1371/journal.pone.0101902.t003
1.937; 95% CI, 1.277–2.940; \( P = 0.002 \). Exploratory analysis revealed no significant interaction between intravenous magnesium supplementation and other covariates (data not shown).

Effect of magnesium supplementation on serum creatinine levels

As shown in Table 2, we found that the prevalence of cisplatin-induced nephrotoxicity was substantially lower in patients who received intravenous magnesium supplementation than in those who did not (6% vs. 37%). To investigate the effect of magnesium supplementation on cisplatin-induced nephrotoxicity, we evaluated the mean change from baseline in the serum creatinine concentration during the first course of high-dose cisplatin therapy. Patients who received magnesium supplementation therapy \( (n = 67) \) showed a mean change in serum creatinine level of \( 0.188 \pm 0.081 \text{ mg/dL} \) (mean ± SE), whereas those who did not receive the treatment \( (n = 334) \) showed a mean change of \( 0.444 \pm 0.043 \text{ mg/dL} \) \( (P = 0.012) \), suggesting that magnesium supplementation therapy limited the elevation of serum creatinine level induced by cisplatin (Figure 1). We further examined how magnesium supplementation might prevent cisplatin-induced nephrotoxicity. Data on the serum magnesium concentration.

Figure 1. Box-and-whisker plot for the relation between intravenous magnesium supplementation and the mean change in serum creatinine concentration during the first course of cisplatin chemotherapy. The difference between the two groups was analyzed with the unpaired Student’s \( t \) test. doi:10.1371/journal.pone.0101902.g001
during the first course of cisplatin chemotherapy were available for 75 of the 401 study patients. No patient showed hypomagnesemia at baseline. Among the 52 patients who received magnesium supplementation, 6 individuals (12%) developed hypomagnesemia of grade 1 or worse, whereas 9 (39%) of the 23 patients who did not receive magnesium supplementation developed this condition ($P = 0.040$), indicating that magnesium supplementation significantly reduced the proportion of patients who developed hypomagnesemia. Furthermore, the 15 patients who developed hypomagnesemia during cisplatin treatment showed a significantly greater mean increase in the serum creatinine concentration from baseline compared with those who maintained a normal level of serum magnesium ($P = 0.0025$) (Figure 2). These results suggest that intravenous magnesium supplementation protects against cisplatin-induced nephrotoxicity by preventing hypomagnesemia.

**Figure 2.** Box-and-whisker plot for the relation between the development of hypomagnesemia and the mean change in serum creatinine concentration during the first course of cisplatin chemotherapy. The difference between the two groups was analyzed with the unpaired Student’s $t$ test. doi:10.1371/journal.pone.0101902.g002
Discussion

Nephrotoxicity remains a clinical problem for 25 to 42% of patients treated with cisplatin [16–18]. In the present study, we found that 32% (127/401) of individuals who received cisplatin at a dose of at least 60 mg/m² developed acute nephrotoxicity despite the adoption of conventional measures of hydration and osmotic diuresis. Although the nephrotoxicity was transient and reversible in most cases, 43% (55/127) of the patients with acute nephrotoxicity went on to develop irreversible renal failure. These results indicate that the conventional prophylactic procedures were not sufficient to prevent cisplatin-induced nephrotoxicity in a subset of patients.

We found that magnesium supplementation therapy was significantly associated with both a reduced frequency and reduced severity of renal toxicity, consistent with previous observations [11,12]. Cisplatin treatment results in a substantial increase in magnesium excretion [19–21], with this effect being apparent even before the onset of overt renal toxicity [22], and hypomagnesemia is associated with cisplatin-induced nephrotoxicity [23]. In the present study, a decrease in the serum magnesium concentration was observed in 20% of patients and was significantly associated with renal toxicity during the first course of cisplatin treatment. Organic cation transporter 2 (OCT2) has been implicated in cisplatin nephrotoxicity in a study with isolated human proximal tubules [24], and hypomagnesemia results in up-regulation of OCT2 and thereby increases the renal accumulation of cisplatin and exacerbates acute kidney injury in an animal model [25]. These various findings suggest that magnesium supplementation protects against cisplatin-induced nephrotoxicity, likely by preventing hypomagnesemia, a notion that warrants validation in a prospective study. The dosage of magnesium sulfate for such supplementation therapy has varied widely in previous studies, ranging from 8 to 60 mEq [9–11,13,26,27], and it therefore remains to be standardized in future trials.

To assess the potential risk factors for cisplatin-induced nephrotoxicity, we performed multivariable analyses. Consistent with previous results [14,28], we found that a poor PS was associated with an increased risk for cisplatin nephrotoxicity. This finding underscores the notion that patients with a PS of 2, which is characterized by an increased risk for severe toxicity in general, need special attention with regard to the potential development of nephrotoxicity during high-dose cisplatin chemotherapy, especially given that such treatment in these patients is controversial [29].

We also found that the regular use of NSAIDs was associated with cisplatin-induced nephrotoxicity. Nonselective inhibition of cyclooxygenases 1 and 2 by NSAIDs attenuates prostaglandin-dependent renal function, including modulation of renal vascular tone and electrolyte and water excretion, in particular during renal stress, as manifested by a reduction in the rate of renal perfusion [30,31]. Such effects of NSAIDs might thus enhance cisplatin-induced nephrotoxicity. Although the significance of the association between the regular use of NSAIDs and cisplatin-induced nephrotoxicity was marginal (P = 0.047) in our analysis, it is of concern because NSAIDs are commonly administered to manage cancer-related pain [32]. Further investigations are thus warranted to evaluate the potential risk of regular NSAID use during high-dose cisplatin chemotherapy.

With regard to tumor type, we found that individuals with esophageal cancer were at a significantly higher risk for cisplatin-induced nephrotoxicity than were those with lung cancer. To our knowledge, such an association has not previously been described.

The median dosage of cisplatin in patients with esophageal cancer was 70 mg/m², which was not higher than that overall (78 mg/m²). Moreover, whereas most patients with esophageal cancer in our analysis were treated with cisplatin together with 5-fluorouracil as the standard care, this regimen was also administered to patients with gastric or head and neck cancer. A difference in dosage or in the combination of chemotherapeutic agents thus could not account for the difference in nephrotoxicity among the malignancies. Caution is necessary in the interpretation of this finding, however, with further study being warranted to determine the mechanism of renal toxicity apparent selectively in patients with esophageal cancer.

Limitations of the present study include possible selection bias of treatment, which is inevitable in a retrospective analysis, and a small sample size for patients with a known serum magnesium concentration and for those who received intravenous magnesium supplementation. Even though all patients treated after July 2011 received magnesium sulfate regardless of their characteristics, cohort effects may still be present that influence the association between magnesium supplementation and nephrotoxicity. In addition, we could not fully assess the incidence and intensity of nonhematologic toxicities in our study as a result of its retrospective nature. Such toxicities, including nausea, vomiting, and diarrhea, might be associated with an increased risk for cisplatin-induced nephrotoxicity. Furthermore, comorbidities relevant to inherent nephrotoxicity, such as proteinuria, hypocalcemia, and renal tubular acidosis, were not assessed in the present study.

In conclusion, our data have revealed a significant association of cisplatin-induced nephrotoxicity with a relatively poor PS and, to a lesser extent, with the regular use of NSAIDs. Our findings also suggest that magnesium supplementation might be effective for protection against the renal toxicity of cisplatin, a conclusion that should be further addressed in a prospective trial.

Supporting Information

Table S1 Chemotherapy regimens according to tumor type. (DOCX)

Table S2 Association between concurrent chemotherapy agents and the occurrence of nephrotoxicity. (DOCX)

Author Contributions

Conceived and designed the experiments: H. Kawakami. Contributed reagents/materials/analysis tools: H. Kawakami. YC. Wrote the paper: YK H. Kawakami. JT YC. Collected the data: YK. Contributed study materials or patients: YK H. Kawakami TS KO KT MT S. Nishina JT KF MN YY S. Nishida TT KN. Analyzed and interpreted the data: YK H. Kawakami YC. Administrative support: S. Nishida TT KN. Contributed in critical revision of the manuscript for important intellectual content: YK H. Kawakami TS KO KT MT H. Kanesu S. Nishina JT KF MN YY YC S. Nishida TT KN.

References

1. Roosnevog M, von Hoff DD, Slavik M, Muggia FM (1977) Cis-diaminidinechloroplatinum II. A new anticancer drug. Ann Intern Med 86: 803–812.
2. Wang D, Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4: 307–320.
Cisplatin Nephrotoxicity and Magnesium Supplementation

5. dos Santos NA, Carvalho Rodrigues MA, Martins NM, dos Santos AC (2012) Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update. Arch Toxicol 86: 1233–1250.

6. Lajer H, Daugaard G (1999) Cisplatin and hypomagnesemia. Cancer Treat Rev 25: 47–58.

7. Netten PM, de Mulder PH, Theeuwes AG, Willems JL, Kohler BE, et al. (1990) Intravenous magnesium supplementation during cis-diammine-dichloroplatinum administration prevents hypomagnesemia. Ann Oncol 1: 369–372.

8. Martin M, Dziura-Rubio E, Casado A, Lopez Vega JM, Saur J, et al. (1992) Intravenous and oral magnesium supplementations in the prophylaxis of cisplatin-induced hypomagnesemia. Results of a controlled trial. Am J Clin Oncol 15: 348–351.

9. Evans TR, Harper CL, Beveridge IG, Wastnage R, Mansi JL (1995) A randomised study to determine whether routine intravenous magnesium supplements are necessary in patients receiving cisplatin chemotherapy with continuous infusion 3-flouroacil. Eur J Cancer 31A: 174–178.

10. Vokes EE, Mick R, Vogelzang NJ, Geiser R, Douglas F (1990) A randomised study comparing intermittent to continuous administration of magnesium aspartate hydrochloride in cisplatin-induced hypomagnesaemia. Br J Cancer 62: 1015–1017.

11. Bodnar L, Wcilo G, Gasowska-Bodnar A, Synowiez A, Szaltej-Wcilo K, et al. (2008) Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: a randomised phase II study. Eur J Cancer 44: 2808–2814.

12. Willox JC, McAllister EJ, Sangster G, Kaye SB (1986) Effects of magnesium supplementation in testicular cancer patients receiving cis-platin: a randomised trial. Br J Cancer 54: 19–23.

13. National Comprehensive Cancer Network (2013) NCCN chemotherapy order templates. Available: http://www.nccn.org/ordertemplates. Accessed: 2013 Nov 11.

14. Stewart DJ, Delberg CS, Mikhail NZ, Redmond MD, Monpeit VA, et al. (1997) Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Cancer Chemother Pharmacol 40: 293–308.

15. Hesketh PJ, Chansky K, Lau DH, Doreshow JH, Moupinor CM, et al. (2006) Sequentinal vinoefibine and doctaxel in advanced non-small cell lung cancer patients age 70 and older and/or with a performance status of 2: a phase II trial of the Southwest Oncology Group (S0027). J Thorac Oncol 1: 537–544.

16. Ries F, Klasterky J (1986) Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis 8: 368–379.

17. Kovach JS, Moertel CG, Schutt AJ, Reitemeier RG, Hahn RG (1973) Phase II study of cis-diammine-dichloroplatinum (NSC-119875) in advanced carcinoma of the large bowel. Cancer Chemother Rep 57: 357–359.

18. de Jongh FE, van Veen KN, Veltman SJ, de Wit R, van der Burg ME, et al. (2003) Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer 88: 1199–1206.

19. Mavicak V, Wong NL, Quamme GA, Magil AB, Sutton RA, et al. (1985) Studies on the pathogenesis of cisplatin-induced hypomagnesemia in rats. Kidney Int 28: 914–921.

20. Stewart AF, Keating T, Schwartz PE, (1985) Magnesium homeostasis following chemotherapy with cisplatin: a prospective study. Am J Obstetr Gynecol 153: 660–665.

21. Arieta G, Rodriguez-Soriano J, Vallo A, Navajas A (1997) Acute and chronic effects of cisplatin therapy on renal magnesium homeostasis. Med Pediatr Oncol 28: 35–40.

22. Daugaard G, Ahlggaard U, Holstein-Rathsou NH, Brunnshaus I, Bucher D, et al. (1988) Renal tubular function in patients treated with high-dose cisplatin. Clin Pharmacol Ther 44: 164–172.

23. Lajer H, Kristensen M, Hansen HH, Nielsen S, Frokiaer J, et al. (2005) Magnesium depletion enhances cisplatin-induced nephrotoxicity. Cancer Chemother Pharmacol 56: 535–542.

24. Ciaramboli G, Ludwig T, Lang D, Ravenstredt H, Koepsell H, et al. (2005) Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol 167: 1477–1484.

25. Yokoo K, Murakami R, Matsuzaki T, Yoshitome K, Hamada A, et al. (2009) Enhanced renal accumulation of cisplatin via renal organic cation transporter deteriorates acute kidney injury in hypomagnesemic rats. Clin Exp Nephrol 13: 570–584.

26. Tiseo M, Martelli O, Mancuso A, Sorinani MP, Bruzzi P, et al. (2007) Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma. Tumori 93: 138–144.

27. Al Bahrain BJ, Moylan EJ, Forouzesh B, Della-Fiorentina SA, Goldtrick AJ (2009) A short outpatient hydration schedule for cisplatin administration. Gult J Oncol 5: 30–36.

28. Sweeney CJ, Zhu J, Sandulli AB, Schiller J, Belani CP, et al. (2001) Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase II trial in patients with metastatic nonsmall cell lung carcinoma. Cancer 92: 2639–2647.

29. Gradell C, Maione P, Rossi A, Guerriero C, Ferraza C, et al. (2006) Chemotherapy of advanced NSCLC in special patient population. Ann Oncol 17 (suppl 5): v72–v78.

30. Whelan A, Maurath CJ, Verbuk KM, Geis GS (2000) Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am J Ther 7: 159–175.

31. Pope JE, Anderson JJ, Felson DT (1993) A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 153: 477–484.

32. Ripamonti CJ, Bandieri E, Roila F (2011) Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol 22 (suppl 6): vi69–vi77.